Identification

Name
Alendronic acid
Accession Number
DB00630  (APRD00561)
Type
Small Molecule
Groups
Approved
Description

Alendronic acid (alendronate) is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Paget’s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Paget’s disease.

Structure
Thumb
Synonyms
  • (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
  • (4-amino-1-hydroxybutylidene)bisphosphonic acid
  • 4-amino-1-hydroxybutane-1,1-diphosphonic acid
  • ABDP
  • Acide Alendronique
  • Acido Alendronico
  • Acidum Alendronicum
  • Alendronate
External IDs
G 704650 / GTH 4 / L 670 / L 670452 / MK 217
Product Ingredients
IngredientUNIICASInChI Key
Alendronate calcium3JTA994BVH137504-90-6VFAZUESUCBECNE-UHFFFAOYSA-L
Alendronate sodium2UY4M2U3RA121268-17-5DCSBSVSZJRSITC-UHFFFAOYSA-M
Alendronate sodium anhydrous4988K7X26P129318-43-0CAKRAHQRJGUPIG-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-alendronateTablet70 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-alendronateTablet5 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-alendronateTablet10 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-alendronateTablet70 mgOralAccord Healthcare Limited2012-03-20Not applicableCanada
Ach-alendronateTablet5 mgOralAccord Healthcare Limited2012-03-20Not applicableCanada
Ach-alendronateTablet10 mgOralAccord Healthcare Limited2012-03-20Not applicableCanada
Act AlendronateTablet40 mgOralActavis Pharma Company2005-06-14Not applicableCanada
Act AlendronateTablet70 mgOralActavis Pharma Company2005-06-14Not applicableCanada
AlendronateTablet70 mgOralSanis Health Inc2010-07-30Not applicableCanada
AlendronateTablet70 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlendronateTablet35 mg/1OralVirtus Pharmaceuticals2015-09-30Not applicableUs
AlendronateTablet70 mg/1OralA S Medication Solutions2015-09-302017-06-20Us
AlendronateTablet70 mg/1OralNu Care Pharmaceuticals,inc.2015-09-30Not applicableUs
AlendronateTablet70 mg/1OralVirtus Pharmaceuticals2015-09-30Not applicableUs
AlendronateTablet35 mg/1OralNu Care Pharmaceuticals,inc.2015-09-30Not applicableUs
Alendronate SodiumTablet70 mg/1OralSun Pharma Global Inc.2008-09-102017-09-05Us
Alendronate SodiumTablet70 mg/1OralRemedy Repack2017-03-03Not applicableUs
Alendronate SodiumTablet10 mg/1OralMylan Institutional2008-09-01Not applicableUs51079 0941 05 nlmimage10 d533eaff
Alendronate SodiumTablet5 mg/1OralTeva2008-02-062018-06-30Us00093 5140 56 nlmimage10 1b2d0df8
Alendronate SodiumTablet70 mg/1OralPreferreed Pharmaceuticals Inc.2016-09-28Not applicableUs
International/Other Brands
Alenotop (Pliva) / Alned (Laboratorios Belmac) / Arendal (Ivax) / Beenos (Gedeon Richter) / Berlex (Duncan) / Denfos (Biofarma) / Densidron (Mepha) / Dronat (Farmavita) / Durost (Perumed) / Fixopan (Grupo Farma) / Forosa (Kemofarmacija) / Fosagen (Aspen Pharmacare) / Fosalen (Teriak) / Fosmin (Hospimedikka) / Fostolin (Actavis) / Fosval (Saval) / Huesobone (Farmaceutica Latina) / Lendrate (Actavis) / Oseolen (Intipharma) / Ostemax (Polpharma)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AdrovanceAlendronate sodium (70 mg) + Cholecalciferol (2800 IU)TabletOralMerck Sharp & Dohme Limited2007-01-04Not applicableEu
AdrovanceAlendronate sodium (70 mg) + Cholecalciferol (5600 IU)TabletOralMerck Sharp & Dohme Limited2007-01-04Not applicableEu
AdrovanceAlendronate sodium (70 mg) + Cholecalciferol (2800 IU)TabletOralMerck Sharp & Dohme Limited2007-01-04Not applicableEu
AdrovanceAlendronate sodium (70 mg) + Cholecalciferol (2800 IU)TabletOralMerck Sharp & Dohme Limited2007-01-04Not applicableEu
AdrovanceAlendronate sodium (70 mg) + Cholecalciferol (5600 IU)TabletOralMerck Sharp & Dohme Limited2007-01-04Not applicableEu
AdrovanceAlendronate sodium (70 mg) + Cholecalciferol (5600 IU)TabletOralMerck Sharp & Dohme Limited2007-01-04Not applicableEu
AdrovanceAlendronate sodium (70 mg) + Cholecalciferol (2800 IU)TabletOralMerck Sharp & Dohme Limited2007-01-04Not applicableEu
Alendronate-cholecalciferolAlendronate sodium (70 mg) + Cholecalciferol (2800 unit)TabletOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Alendronate-cholecalciferolAlendronate sodium (70 mg) + Cholecalciferol (5600 unit)TabletOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Apo-alendronate/vitamin D3Alendronate sodium (70 mg) + Cholecalciferol (2800 unit)TabletOralApotex Corporation2016-07-21Not applicableCanada
Categories
UNII
X1J18R4W8P
CAS number
66376-36-1
Weight
Average: 249.096
Monoisotopic: 249.016724799
Chemical Formula
C4H13NO7P2
InChI Key
OGSPWJRAVKPPFI-UHFFFAOYSA-N
InChI
InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
IUPAC Name
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
SMILES
NCCCC(O)(P(O)(O)=O)P(O)(O)=O

Pharmacology

Indication

For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.

Structured Indications
Pharmacodynamics

Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women.

Mechanism of action

The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

TargetActionsOrganism
AFarnesyl pyrophosphate synthase
inhibitor
Human
AHydroxylapatite
antagonist
Human
UTyrosine-protein phosphatase non-receptor type 4
inhibitor
Human
UReceptor-type tyrosine-protein phosphatase S
inhibitor
Human
UReceptor-type tyrosine-protein phosphatase epsilon
inhibitor
Human
UV-type proton ATPase catalytic subunit A
inhibitor
Human
Absorption

Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast.

Volume of distribution
  • 28 L
Protein binding

78%

Metabolism

There is no evidence that alendronate is metabolized in humans or animals.

Route of elimination

Following a single IV dose of [14C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces.

Half life

>10 years

Clearance
  • <200 mL/min [A single 10 mg IV dose]
Toxicity

Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis."

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Alendronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.Approved, Vet Approved
AclarubicinAclarubicin may increase the hypocalcemic activities of Alendronic acid.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Alendronic acid.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Alendronic acid.Approved, Withdrawn
AlgeldrateThe serum concentration of Alendronic acid can be decreased when it is combined with Algeldrate.Approved, Experimental
AlmagateThe serum concentration of Alendronic acid can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Alendronic acid can be decreased when it is combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Alendronic acid.Experimental
AloglutamolThe serum concentration of Alendronic acid can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
AmikacinAmikacin may increase the hypocalcemic activities of Alendronic acid.Approved, Vet Approved
AmrubicinAmrubicin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Alendronic acid.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alendronic acid.Investigational
annamycinannamycin may increase the hypocalcemic activities of Alendronic acid.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Alendronic acid.Investigational
ApramycinApramycin may increase the hypocalcemic activities of Alendronic acid.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Alendronic acid.Approved, Investigational
ArbekacinArbekacin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Alendronic acid.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.Approved, Investigational
BekanamycinBekanamycin may increase the hypocalcemic activities of Alendronic acid.Experimental
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Alendronic acid.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Alendronic acid.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alendronic acid.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Alendronic acid.Experimental
Bismuth SubcitrateThe serum concentration of Alendronic acid can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Alendronic acid can be decreased when it is combined with Bismuth subnitrate.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alendronic acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alendronic acid.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Alendronic acid.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Alendronic acid.Experimental
Calcium AcetateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Acetate.Approved
Calcium CarbonateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Carbonate.Approved
Calcium ChlorideThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Chloride.Approved
Calcium CitrateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium laevulateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium laevulate.Experimental
Calcium pangamateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium silicate.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alendronic acid.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Alendronic acid.Approved, Vet Approved, Withdrawn
CaseinThe serum concentration of Alendronic acid can be decreased when it is combined with Casein.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alendronic acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alendronic acid.Approved, Vet Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alendronic acid.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Alendronic acid.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Alendronic acid.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Alendronic acid.Investigational
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Alendronic acid.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Alendronic acid is combined with Deferasirox.Approved, Investigational
DexlansoprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole.Approved
DexrabeprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexrabeprazole.Experimental
DibekacinDibekacin may increase the hypocalcemic activities of Alendronic acid.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid.Approved, Vet Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Alendronic acid.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.Approved
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Alendronic acid.Investigational, Vet Approved
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alendronic acid.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Alendronic acid.Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Alendronic acid.Approved
EpirubicinEpirubicin may increase the hypocalcemic activities of Alendronic acid.Approved
EsomeprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Alendronic acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Alendronic acid.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Alendronic acid.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Alendronic acid.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Alendronic acid.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Alendronic acid.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Alendronic acid.Experimental
Ferric CitrateThe serum concentration of Alendronic acid can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Alendronic acid.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Alendronic acid.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Alendronic acid.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Alendronic acid.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.Approved, Investigational
FramycetinFramycetin may increase the hypocalcemic activities of Alendronic acid.Approved
GeneticinGeneticin may increase the hypocalcemic activities of Alendronic acid.Experimental
GentamicinGentamicin may increase the hypocalcemic activities of Alendronic acid.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the hypocalcemic activities of Alendronic acid.Experimental
GPX-150GPX-150 may increase the hypocalcemic activities of Alendronic acid.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Alendronic acid.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Alendronic acid.Investigational
HydrotalciteThe serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
Hygromycin BHygromycin B may increase the hypocalcemic activities of Alendronic acid.Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Alendronic acid.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Alendronic acid.Approved
IdarubicinIdarubicin may increase the hypocalcemic activities of Alendronic acid.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Alendronic acid.Experimental
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Alendronic acid.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alendronic acid.Withdrawn
INNO-206INNO-206 may increase the hypocalcemic activities of Alendronic acid.Investigational
Iron saccharateThe serum concentration of Alendronic acid can be decreased when it is combined with Iron saccharate.Approved
IsepamicinIsepamicin may increase the hypocalcemic activities of Alendronic acid.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alendronic acid.Withdrawn
KanamycinKanamycin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.Approved
LansoprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Alendronic acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alendronic acid.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Alendronic acid.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alendronic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alendronic acid.Approved, Investigational
Magnesium HydroxideThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alendronic acid.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid.Investigational, Withdrawn
MetrizamideMetrizamide may increase the hypocalcemic activities of Alendronic acid.Approved
MicronomicinMicronomicin may increase the hypocalcemic activities of Alendronic acid.Experimental
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alendronic acid.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Alendronic acid.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alendronic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Alendronic acid.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Alendronic acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid.Approved, Vet Approved
NeamineNeamine may increase the hypocalcemic activities of Alendronic acid.Experimental
NeomycinNeomycin may increase the hypocalcemic activities of Alendronic acid.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alendronic acid.Approved
NetilmicinNetilmicin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Alendronic acid.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alendronic acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alendronic acid.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alendronic acid.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.Approved
OmeprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Alendronic acid.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.Approved, Withdrawn
PantoprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.Approved
Parathyroid hormoneThe therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.Approved
ParomomycinParomomycin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Alendronic acid.Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alendronic acid.Approved, Investigational
PirarubicinPirarubicin may increase the hypocalcemic activities of Alendronic acid.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alendronic acid.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Alendronic acid.Experimental
PlazomicinPlazomicin may increase the hypocalcemic activities of Alendronic acid.Investigational
PlicamycinPlicamycin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational, Withdrawn
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Alendronic acid.Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Alendronic acid.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alendronic acid.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Alendronic acid.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Alendronic acid.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Alendronic acid.Investigational
PuromycinPuromycin may increase the hypocalcemic activities of Alendronic acid.Experimental
RabeprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid.Approved, Experimental, Investigational
RibostamycinRibostamycin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Alendronic acid.Investigational, Withdrawn
SabarubicinSabarubicin may increase the hypocalcemic activities of Alendronic acid.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Alendronic acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alendronic acid.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alendronic acid.Investigational
SisomicinSisomicin may increase the hypocalcemic activities of Alendronic acid.Investigational
SP1049CSP1049C may increase the hypocalcemic activities of Alendronic acid.Investigational
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational, Vet Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Alendronic acid.Investigational
StreptomycinStreptomycin may increase the hypocalcemic activities of Alendronic acid.Approved, Vet Approved
StreptozocinStreptozocin may increase the hypocalcemic activities of Alendronic acid.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Alendronic acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Alendronic acid.Experimental
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Alendronic acid.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Alendronic acid.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Alendronic acid.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alendronic acid.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alendronic acid.Investigational
TobramycinTobramycin may increase the hypocalcemic activities of Alendronic acid.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alendronic acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Alendronic acid.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Alendronic acid.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Alendronic acid.Investigational
TromethamineThe serum concentration of Alendronic acid can be decreased when it is combined with Tromethamine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.Investigational, Withdrawn
ValrubicinValrubicin may increase the hypocalcemic activities of Alendronic acid.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Alendronic acid.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.Withdrawn
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the hypocalcemic activities of Alendronic acid.Investigational
ZorubicinZorubicin may increase the hypocalcemic activities of Alendronic acid.Experimental
Food Interactions
  • Take 30-60 minutes before breakfast.
  • Take with a full glass of water.

References

Synthesis Reference

Masahiko Dohi, Yuji Makino, Takao Hujii, "Sodium alendronate preparation for local administration." U.S. Patent US5958908, issued September, 1997.

US5958908
General References
  1. Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [PubMed:18214569]
External Links
Human Metabolome Database
HMDB01915
KEGG Compound
C07752
PubChem Compound
2088
PubChem Substance
46507199
ChemSpider
2004
BindingDB
25313
ChEBI
2567
ChEMBL
CHEMBL870
Therapeutic Targets Database
DAP000182
PharmGKB
PA448082
HET
212
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Alendronate
ATC Codes
M05BA04 — Alendronic acidM05BB03 — Alendronic acid and colecalciferolM05BB05 — Alendronic acid, calcium and colecalciferol, sequentialM05BB06 — Alendronic acid and alfacalcidol, sequential
AHFS Codes
  • 92:24.00 — Bone Resorption Inhibitors
PDB Entries
5dz2
FDA label
Download (105 KB)
MSDS
Download (24.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers3
1CompletedNot AvailableBone destruction / Osteopenia1
1CompletedPreventionViral Hepatitis B1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentBone destruction2
1RecruitingPreventionNeoplasms, Breast1
2Active Not RecruitingTreatmentBone destruction / Bone Loss / Spinal Cord Injuries (SCI)1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Active Not RecruitingTreatmentBone destruction1
2CompletedPreventionCancer, Ovarian1
2CompletedTreatmentChronic Periodontitis1
2CompletedTreatmentGaucher's Disease / Osteopenia1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentLow Bone Mineral Density1
2CompletedTreatmentLow Bone Mineral Density / Postmenopausal Osteoporosis (PMO)1
2CompletedTreatmentPolyostotic Fibrous Dysplasia1
2CompletedTreatmentPostmenopausal Osteoporosis (PMO)1
2CompletedTreatmentBone destruction / Postmenopausal Osteoporosis (PMO)1
2CompletedTreatmentBone destruction6
2RecruitingTreatmentCalcific Aortic Stenosis1
2RecruitingTreatmentBone destruction / Rheumatoid Arthritis1
2SuspendedTreatmentBone destruction / Hypogonadism / Osteopenia1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Bone Metastases / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2TerminatedTreatmentBone destruction1
2Unknown StatusTreatmentOsteoporosis, Post-Menopausal1
2, 3CompletedPreventionBone Resorption / Heart Transplantation / Transplantation, Liver1
2, 3CompletedTreatmentAsthma Bronchial1
2, 3CompletedTreatmentChronic Periodontitis3
2, 3CompletedTreatmentGlucocorticoid-Associated Osteopenia and Osteoporosis1
2, 3RecruitingPreventionOsteoporosis, Steroid Induced1
2, 3Unknown StatusTreatmentBone destruction / Osteopenia1
3CompletedDiagnosticBone destruction / Cancer, Breast1
3CompletedPreventionCancer, Breast1
3CompletedPreventionBone destruction / Cardiac Transplantation1
3CompletedPreventionBone destruction / Hypogonadism / Prostate Cancer1
3CompletedPreventionOsteopenia1
3CompletedTreatmentBone destruction / Cystic Fibrosis (CF)1
3CompletedTreatmentBone destruction / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentBone destruction / Osteopenia1
3CompletedTreatmentPaget's Disease of Bone1
3CompletedTreatmentPostmenopausal Osteoporosis (PMO)3
3CompletedTreatmentPostmenopausal Women With Osteoporosis1
3CompletedTreatmentProstatic Neoplasms1
3CompletedTreatmentBone destruction6
3TerminatedPreventionBone destruction1
3TerminatedTreatmentBone destruction / Cerebral Palsy (CP)1
3TerminatedTreatmentBone destruction / Osteopenia1
3TerminatedTreatmentBone destruction1
3Unknown StatusPreventionBone destruction1
3Unknown StatusTreatmentBone destruction1
3WithdrawnTreatmentBone destruction / Postmenopausal Osteoporosis (PMO)1
4CompletedNot AvailableAnkylosing Spondylitis (AS) / Bone destruction1
4CompletedPreventionArteriosclerosis / Calcifications, Vascular1
4CompletedPreventionBone destruction / Cystic Fibrosis (CF) / Muscular Dystrophy1
4CompletedPreventionBone destruction / Osteopenia1
4CompletedTreatmentBone destruction / Bone Diseases, Metabolic / Cystic Fibrosis (CF)1
4CompletedTreatmentCardiorenal Syndrome / Chronic Allograft Nephropathy (CAN)1
4CompletedTreatmentBone destruction / Depression / Healthy Volunteers / Osteopenia1
4CompletedTreatmentBone destruction / End-Stage Renal Disease (ESRD)1
4CompletedTreatmentIntrabony Periodontal Defect1
4CompletedTreatmentOsteogenesis Imperfecta1
4CompletedTreatmentBone destruction / Osteogenesis Imperfecta / Paget's Disease of Bone1
4CompletedTreatmentOsteoporosis, Post-Menopausal1
4CompletedTreatmentPostmenopausal Osteoporosis (PMO)3
4CompletedTreatmentBone destruction / Primary Hyperparathyroidism1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentBone destruction5
4Not Yet RecruitingTreatmentDepressive Syndrome1
4RecruitingPreventionBone Demineralization1
4RecruitingTreatmentBone destruction1
4TerminatedTreatmentBack Pain1
4Unknown StatusPreventionNon-Traumatic Osteonecrosis1
4Unknown StatusTreatmentPeritoneal dialysis therapy1
4WithdrawnTreatmentHyperparathyroidism1
Not AvailableActive Not RecruitingNot AvailableLow Bone Density1
Not AvailableCompletedNot AvailableAdenocarcinomas / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
Not AvailableCompletedNot AvailableFracture Bone / Juvenile Osteoporosis / Low Bone Density1
Not AvailableCompletedNot AvailablePerimenopausal Bone Loss1
Not AvailableCompletedNot AvailablePostmenopausal Osteoporosis (PMO)1
Not AvailableCompletedNot AvailableBone destruction1
Not AvailableCompletedBasic SciencePrimary Hyperparathyroidism1
Not AvailableCompletedDiagnosticKidney (Renal Cell) Cancer / Neoplasms, Kidney / Renal Cell Adenocarcinoma1
Not AvailableCompletedTreatmentBone destruction / Cystic Fibrosis (CF)1
Not AvailableCompletedTreatmentBone destruction / Osteopenia1
Not AvailableCompletedTreatmentBone destruction1
Not AvailableEnrolling by InvitationNot AvailableAtypical Femoral Fractures / Bisphosphonate Therapy / Bone destruction1
Not AvailableRecruitingTreatmentBone destruction / Differentiated Thyroid Cancer (DTC)1
Not AvailableRecruitingTreatmentKidney Failure,Chronic1
Not AvailableTerminatedNot AvailableBone destruction1
Not AvailableTerminatedPreventionBone destruction / Spinal Cord Injuries (SCI)1
Not AvailableUnknown StatusTreatmentArthroplasty, Replacement, Hip / Bone Density1
Not AvailableUnknown StatusTreatmentImpaired Renal Function1

Pharmacoeconomics

Manufacturers
  • Merck and co inc
  • Apotex inc
  • Aurobindo pharma ltd
  • Austarpharma llc
  • Barr laboratories inc
  • Cadista pharmaceuticals inc
  • Dr reddys laboratories ltd
  • Genpharm ulc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Sun pharma global inc
  • Teva pharmaceuticals usa
  • Watson laboratories
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
SolutionOral70 mg/75mL
TabletOral10 mg/1
TabletOral35 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral70 mg/1
Tablet, effervescentOral70 mg/1
SolutionOral70 mg
TabletOral40 mg
TabletOral70 mg
Tablet, coatedOral10 mg/1
TabletOral
TabletOral10.0 mg
TabletOral5.0 mg
TabletOral70.0 mg
TabletOral10 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Fosamax Plus D 4 70-2800 mg-Unit tablet Disp Pack107.66USD disp
Fosamax Plus D 4 70-5600 mg-Unit tablet Disp Pack107.66USD disp
Fosamax 1 Package = 4 tablet (70 mg) Package101.96USD package
Fosamax 1 Package = 4 tablet (35 mg) Package97.2USD package
Alendronate Sodium 4 35 mg tablet Package85.23USD package
Alendronate Sodium 4 70 mg tablet Package85.23USD package
Fosamax 70 mg/75ml Solution 75ml Bottle34.75USD bottle
Fosamax plus d 70 mg-5600 iu25.88USD each
Fosamax 70 mg tablet24.51USD tablet
Fosamax 35 mg tablet23.36USD tablet
Fosamax plus d 70 mg-2800 iu21.85USD each
Alendronate sodium 35 mg tablet20.49USD tablet
Alendronate sodium 70 mg tablet20.49USD tablet
Fosamax 40 mg tablet7.52USD tablet
Alendronate sodium 40 mg tablet6.73USD tablet
Fosamax 5 mg tablet3.4USD tablet
Fosamax 10 mg tablet3.4USD tablet
Alendronate sodium 10 mg tablet2.99USD tablet
Alendronate sodium 5 mg tablet2.99USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5358941No1992-12-022012-12-02Us
CA2190148No2006-02-142015-05-12Canada
CA2294595No2001-08-212018-07-17Canada
US5994329Yes1999-01-172019-01-17Us
US6015801Yes1999-01-172019-01-17Us
US6225294Yes1999-01-172019-01-17Us
US7964212No2003-03-062023-03-06Us
US7488496No2003-08-112023-08-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)234 dec °CPhysProp
water solubility1mg/LNot Available
logP-4.3Not Available
pKa2.72 (at 25 °C)MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility16.9 mg/mLALOGPS
logP-1.3ALOGPS
logP-4.2ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)0.69ChemAxon
pKa (Strongest Basic)9.91ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area161.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity47.37 m3·mol-1ChemAxon
Polarizability19.4 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9554
Blood Brain Barrier+0.7065
Caco-2 permeable-0.7079
P-glycoprotein substrateNon-substrate0.6606
P-glycoprotein inhibitor INon-inhibitor0.947
P-glycoprotein inhibitor IINon-inhibitor0.9894
Renal organic cation transporterNon-inhibitor0.9205
CYP450 2C9 substrateNon-substrate0.8536
CYP450 2D6 substrateNon-substrate0.7997
CYP450 3A4 substrateNon-substrate0.6792
CYP450 1A2 substrateNon-inhibitor0.7567
CYP450 2C9 inhibitorNon-inhibitor0.9089
CYP450 2D6 inhibitorNon-inhibitor0.9344
CYP450 2C19 inhibitorNon-inhibitor0.9091
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9914
Ames testNon AMES toxic0.7079
CarcinogenicityNon-carcinogens0.7783
BiodegradationReady biodegradable0.6547
Rat acute toxicity1.6956 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8571
hERG inhibition (predictor II)Non-inhibitor0.8929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-014i-2930000000-99692afb4ed253251947
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-001i-0900000000-d2c07307d66e1c7d52e8
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0kdl-9500000000-c82a6e6e898154627c7d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Organic phosphonic acids / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
Substituents
Bisphosphonate / Organophosphonic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Primary amine / Organophosphorus compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
primary amino compound, 1,1-bis(phosphonic acid) (CHEBI:2567)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [PubMed:10620343]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
  4. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH: Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29. [PubMed:17535895]
Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Non-membrane spanning protein tyrosine phosphatase activity
Specific Function
May act at junctions between the membrane and the cytoskeleton.
Gene Name
PTPN4
Uniprot ID
P29074
Uniprot Name
Tyrosine-protein phosphatase non-receptor type 4
Molecular Weight
105910.315 Da
References
  1. Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7. [PubMed:9310349]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transmembrane receptor protein tyrosine phosphatase activity
Specific Function
Interacts with LAR-interacting protein LIP.1.
Gene Name
PTPRS
Uniprot ID
Q13332
Uniprot Name
Receptor-type tyrosine-protein phosphatase S
Molecular Weight
217039.825 Da
References
  1. Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7. [PubMed:9310349]
  2. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. [PubMed:8610169]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transmembrane receptor protein tyrosine phosphatase activity
Specific Function
Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells. May play a role in osteoclast formation and function (By similarity).Isofo...
Gene Name
PTPRE
Uniprot ID
P23469
Uniprot Name
Receptor-type tyrosine-protein phosphatase epsilon
Molecular Weight
80641.165 Da
References
  1. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. [PubMed:8610169]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-transporting atpase activity, rotational mechanism
Specific Function
Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.
Gene Name
ATP6V1A
Uniprot ID
P38606
Uniprot Name
V-type proton ATPase catalytic subunit A
Molecular Weight
68303.5 Da
References
  1. David P, Nguyen H, Barbier A, Baron R: The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996 Oct;11(10):1498-507. [PubMed:8889850]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34